chr1-161307376-T-G
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM1PM2PP3PP5_Very_Strong
The ENST00000533357.5(MPZ):āc.116A>Cā(p.His39Pro) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000657 in 152,252 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. H39Q) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000533357.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MPZ | NM_000530.8 | c.116A>C | p.His39Pro | missense_variant | 2/6 | ENST00000533357.5 | NP_000521.2 | |
MPZ | NM_001315491.2 | c.116A>C | p.His39Pro | missense_variant | 2/6 | NP_001302420.1 | ||
MPZ | XM_017001321.3 | c.146A>C | p.His49Pro | missense_variant | 2/6 | XP_016856810.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MPZ | ENST00000533357.5 | c.116A>C | p.His39Pro | missense_variant | 2/6 | 1 | NM_000530.8 | ENSP00000432943 | P1 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152252Hom.: 0 Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152252Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74378
ClinVar
Submissions by phenotype
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Oct 21, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 25, 2024 | Published functional studies demonstrate a damaging effect: partial loss of function (PMID: 18337304); Not observed in large population cohorts (gnomAD); Missense variants in this gene are often considered pathogenic (HGMD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 26310628, 29687021, 14711881, 17602703, 16844954, 20461396, 18337304) - |
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Oct 24, 2022 | This variant associates in multiple families with clinical features of Charcot-Marie Tooth disease. This variant has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). This variant occurs as the most likely explanation for disease in a significant number of cases, suggesting this variant is associated with disease. - |
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Feb 21, 2023 | The MPZ c.116A>C; p.His39Pro variant (rs371856018) is reported in the literature in numerous individuals affected with Charcot-Marie-Tooth syndrome or neuropathy (Kilfoyle 2006, Sanmaneechai 2015, Shy 2004, Souayah 2007). This variant was observed to co-segregate with disease in multiple families (Kilfoyle 2006, Shy 2004, Souayah 2007), including one large family where it was observed in 10 affected individuals and was absent from 24 unaffected individuals (Kilfoyle 2006). This variant is absent from the Genome Aggregation Database, indicating it is not a common polymorphism. Based on available information, including its occurrence in a large number of affected individuals, this variant is considered to be pathogenic. References: Kilfoyle DH et al. Myelin protein zero mutation His39Pro: hereditary motor and sensory neuropathy with variable onset, hearing loss, restless legs and multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006 Aug;77(8):963-6. Sanmaneechai O et al. Genotype-phenotype characteristics and baseline natural history of heritable neuropathies caused by mutations in the MPZ gene. Brain. 2015 Nov;138(Pt 11):3180-92. Shy ME et al. Phenotypic clustering in MPZ mutations. Brain. 2004 Feb;127(Pt 2):371-84. Souayah N et al. Rare myelin protein zero sequence variant in late onset CMT1B. J Neurol Sci. 2007 Dec 15;263(1-2):177-9. - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 21, 2022 | The c.116A>C (p.H39P) alteration is located in exon 2 (coding exon 2) of the MPZ gene. This alteration results from a A to C substitution at nucleotide position 116, causing the histidine (H) at amino acid position 39 to be replaced by a proline (P). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This variant has been reported in multiple individuals with adult-onset demyelinating Charcot-Marie-Tooth disease type 1B and cosegregates with disease in two families (Shy, 2004; Kilfoyle, 2006; Souayah, 2007). This amino acid position is not well conserved in available vertebrate species. This alteration was found to be functionally abnormal in an assay of MPZ-mediated intercellular adhesion (Grandis, 2008). This alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. - |
Charcot-Marie-Tooth disease type 1B Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Jun 12, 2024 | Criteria applied: PS3,PM1,PS4_SUP,PM2_SUP - |
MPZ-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 15, 2024 | Variant summary: MPZ c.116A>C (p.His39Pro) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant was absent in 251300 control chromosomes. c.116A>C has been reported in the literature in multiple individuals affected with MPZ-Related Disorders. These data indicate that the variant is very likely to be associated with disease. ClinVar contains an entry for this variant (Variation ID: 217232). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Charcot-Marie-Tooth disease, type I Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 11, 2024 | This sequence change replaces histidine, which is basic and polar, with proline, which is neutral and non-polar, at codon 39 of the MPZ protein (p.His39Pro). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with Charcot-Marie-Tooth disease (CMT) (PMID: 14711881, 16844954, 17602703, 26310628). It has also been observed to segregate with disease in related individuals. This variant is also known as p.His10Pro. ClinVar contains an entry for this variant (Variation ID: 217232). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on MPZ protein function. Experimental studies have shown that this missense change affects MPZ function (PMID: 18337304). For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at